EDINBURGH, Scotland, Jan. 29,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a
clinical stage biotechnology company developing platform allogeneic
gamma-delta T cell therapies for cancer, today announced that its
Chief Executive Officer, Bryan Kobel, was featured in live
interview with the "Big Biz Show," an Emmy Award-winning nationally
syndicated TV and radio show.
Click here for Interview:
https://www.youtube.com/watch?v=oAUXEBV20oo&t=41s
The interview will be aired on cable TV and streaming services,
including Roku, as well as on radio via The Biz Talk Radio Network,
Armed Forces Radio, and iHeart Media in 175 countries. Podcasts of
the show will be available on iHeart Radio, Apple Podcasts,
Speaker.com, and TuneIn, as well as to subscribers of biztv.com or
ytaclub.com.
About the Big Biz Show
Widely regarded as "Business
with a Bite," the Big Biz Show is an Emmy Award-winning nationally
syndicated radio and TV program. The fast-talking, hard-hitting
show is hosted by Bob "Sully" Sullivan, who is also a weekly
contributor on the FOX Business Network. For more information, go
to bigbizshow.com.
About TC BioPharm (Holdings) PLC
TC BioPharm is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of gamma-delta T cell therapies
for the treatment of cancer with human efficacy data in acute
myeloid leukemia. Gamma-delta T cells are naturally occurring
immune cells that embody properties of both the innate and adaptive
immune systems and can intrinsically differentiate between healthy
and diseased tissue. TC BioPharm uses an allogeneic approach to
effectively identify, target and eradicate both liquid and solid
tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia using the Company's proprietary allogenic
CryoTC technology to provide frozen product to clinics worldwide.
TC BioPharm also maintains a robust pipeline for future indications
in solid tumors as well as a significant IP/patent portfolio and
owns its manufacturing facility to maintain cost and product
quality controls.
Forward Looking Statements
This press release may contain statements of a forward-looking
nature relating to future events. These forward-looking statements
are subject to the inherent uncertainties in predicting future
results and conditions. These statements reflect our current
beliefs, and a number of important factors could cause actual
results to differ materially from those expressed in this press
release. We undertake no obligation to revise or update any
forward-looking statements, whether as a result of new information,
future events or otherwise. The reference to the website of TC
BioPharm has been provided as a convenience, and the information
contained on such website is not incorporated by reference into
this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-chief-executive-officer-bryan-kobel-featured-on-the-big-biz-show-302046671.html
SOURCE TC BioPharm